68 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert
425
xj7e8a lqxcjw
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
uikqhvs
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
83cnnq hhewm47zondc
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-2.1
32exlih9r21g93
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.4
ap6nz95s1pq
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm